Table 3:
Main Findings of the Included Study
| Variable | Home NB-UVB Phototherapy | Outpatient NB-UVB Phototherapy | Difference (95% CI) |
|---|---|---|---|
| Area and Severity of Disease | |||
| SAPASI 50, 75, 90a | (n = 94) | (n = 91) | |
| SAPASI 50, % | 81.9 (n = 77) | 79.1 (n = 72) | 2.8 (−8.6 to 14.2) |
| SAPASI 75, % | 69.1 (n = 65) | 59.3 (n = 54) | 9.8 (−4.0 to 23.6) |
| SAPASI 90, % | 43.6 (n = 41) | 29.7 (n = 27) | 13.9 (0.002 to 27.8) |
| PASI 50, 75, 90b | (n = 91) | (n = 84) | |
| PASI 50, % | 70.3 (n = 64) | 72.6 (n = 61) | −2.3 (−15.7 to 11.1) |
| PASI 75, % | 40.7 (n = 37) | 41.7 (n = 35) | −1.0 (−15.6 to 13.6) |
| PASI 90, % | 19.8 (n = 18) | 19.0 (n = 16) | 0.8 (−10.9 to 12.5) |
| Quality of Life | |||
| PDI, change from baseline | −11.9 (SE NR) End: 20.9 | −12.3 (SE NR) End: 22.0 | 0.4c |
| Baseline: 32.8 | Baseline: 34.3 | ||
| SF-36d | NR | NR | NR |
| Safety | |||
| Percentage of side effects per irradiation | (n = 93) | (n = 92) | |
| Mild erythema | 28.8 | 28.6 | 0.3 (−7.4 to 8.0) |
| Burning sensation | 7.1 | 10.0 | −2.9 (−7.1 to 1.2) |
| Severe erythema | 5.5 | 3.6 | 1.9 (−1.1 to 4.9) |
| Blistering | 0.3 | 0.6 | −0.3 (−0.9 to 0.3) |
Abbreviations: CI, confidence interval; NB-UVB, narrowband ultraviolet B; NR, not reported; PASI, Psoriasis Area and Severity Index; PDI, Psoriasis Disability Index; SAPASI, Self-Administered Psoriasis Area and Severity Index; SE, standard error; SF-36, 36-Item Short-Form Survey
a
The proportion of participants achieving an improvement of at least 50%, 75%, or 90% over their baseline SAPASI scores.
b
The proportion of participants achieving an improvement of at least 50%, 75%, or 90% over their baseline PASI scores.
c
Insufficient information was available to compute the confidence interval.
d
The authors did not report any estimates; they stated only that both groups experienced an improvement.